このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

BeyondSpring マネジメント

マネジメント基準チェック /24

BeyondSpring'sの CEO はLan Huangで、 Nov2014年に任命され、の在任期間は 9.58年です。は、会社の株式の23.88%を直接所有しており、その価値は$ 21.99M 。経営陣と取締役会の平均在任期間はそれぞれ4.6年と4.7年です。

主要情報

Lan Huang

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	9.7yrs
CEOの所有権	23.9%
経営陣の平均在職期間	4.7yrs
取締役会の平均在任期間	4.8yrs

経営陣の近況

Recent updates

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Sep 07

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Aug 01

BeyondSpring EPS misses by $0.04

Jun 16

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

Jun 07

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

Jun 01

BeyondSpring EPS misses by $0.17

Apr 30

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

Dec 22

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

Dec 15

BeyondSpring slides 9% on public offering pricing at $10.0/share

Nov 19

BeyondSpring under pressure on shares offering

Nov 17

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

Nov 16

CEO（最高経営責任者

Lan Huang (53 yo)

9.7yrs

在職期間

Dr. Lan Huang, Ph D., is Founder, Chairman, Chief Executive Officer and Member of Scientific Advisory Board of Seed Therapeutics, Inc. Dr. Huang co-founded BeyondSpring Pharmaceuticals, Inc. in 2013 and se...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Lan Huang	Co-Founder	9.7yrs	データなし	23.88% $ 23.0m
June Lu	Chief Scientific Officer	less than a year	データなし	0.00026% $ 250.6
Linqing Jia	Co-Founder	no data	データなし	0.35% $ 338.5k
Stephen Kilmer	Head of Investor Relations	no data	データなし	データなし
Gregg Russo	Senior Vice President of Human Resources	4.7yrs	データなし	データなし

4.7yrs

平均在職期間

経験豊富な経営陣: BYSIの経営陣は経験豊富であると考えられます ( 4.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Lan Huang	Co-Founder	9.7yrs	データなし	23.88% $ 23.0m
Matthew Kirkby	Independent Director	7.8yrs	データなし	0.016% $ 15.5k
Patrick Fabbio	Independent Director	6.5yrs	データなし	0.063% $ 60.7k
Douglas Blayney	Member of Scientific Advisors & Principal Investigators Board	no data	データなし	データなし
Brendan Delaney	Independent Director	3yrs	データなし	0% $ 0
Yan Sun	Member of Scientific Advisors & Principal Investigators Board	no data	データなし	データなし
Jeffrey Crawford	Member of Scientific Advisors & Principal Investigators Board	no data	データなし	データなし
Yuankai Shi	Member of Scientific Advisors & Principal Investigators Board	no data	データなし	データなし
David Ettinger	Member of Scientific Advisors & Principal Investigators Board	no data	データなし	データなし
Sihai Xu	Director	1.9yrs	データなし	0% $ 0
Jiangwen Majeti	Independent Director	1.9yrs	データなし	0.13% $ 125.8k

4.8yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: BYSIの取締役会は経験豊富であると考えられます ( 4.7年の平均在任期間)。

BeyondSpring マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director

BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023

BeyondSpring Inc. Announces Board Appointments

BeyondSpring Inc. Announces Executive Resignations, with Effect from June 9, 2022

BeyondSpring Inc. Announces Resignation of Gordon L. Schooley as Chief Regulatory Officer

Elizabeth Czerepak Resigns as Executive Vice President of BeyondSpring Inc

Recent updates

New minor risk - Market cap size

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Rule

First half 2023 earnings released: US$0.33 loss per share (vs US$0.47 loss in 1H 2022)

New major risk - Revenue and earnings growth

BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin’s Immunomodulating Activity

New minor risk - Financial data availability

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$2.30

BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

BeyondSpring Inc. Announces Board Appointments

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 2000 Dynamic Index

BeyondSpring Inc. Announces Executive Resignations, with Effect from June 9, 2022

BeyondSpring Inc. Announces Resignation of Gordon L. Schooley as Chief Regulatory Officer

Price target decreased to US$6.10

Elizabeth Czerepak Resigns as Executive Vice President of BeyondSpring Inc

Consensus forecasts updated

Price target increased to US$13.67

BeyondSpring Inc. to Report Q4, 2021 Results on Apr 14, 2022

BeyondSpring, Beyond Salvage

BeyondSpring Pharmaceuticals Announces Organizational Streamlining

Consensus revenue estimates fall by 90%

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in Prevention of Chemotherapy-Induced Neutropenia at 63rd ASH Annual Meeting and Exposition

Consensus forecasts updated

BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)

No longer forecast to breakeven

Circling Back On BeyondSpring

Price target decreased to US$58.60

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Price target increased to US$67.25

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Consensus forecasts updated

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Value Index

Consensus forecasts updated

BeyondSpring EPS misses by $0.04

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

BeyondSpring Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

BeyondSpring EPS misses by $0.17

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

Chief Scientific Officer has left the company

BeyondSpring Inc. Announces Management Changes

Price target lowered to US$36.00

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

BeyondSpring Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

BeyondSpring slides 9% on public offering pricing at $10.0/share

BeyondSpring Announces Positive Topline Results from Its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia

BeyondSpring under pressure on shares offering

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

New 90-day high: US$16.02

BeyondSpring Forms Partnership Advisory Committee

New 90-day high: US$15.36

BeyondSpring Inc. Announces JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy

BeyondSpring Inc. Announces New Clinical Data on Late-Stage Asset, Plinabulin

BeyondSpring Inc. Appoints Elizabeth Czerepak as Chief Financial Officer

マネジメント基準チェック /24